Agios Pharmaceuticals Receives “Overweight” Rating from JPMorgan Chase & Co. (AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “overweight” rating reiterated by research analysts at JPMorgan Chase & Co. in a report released on Monday. They currently have a $60.00 price objective on the stock, up from their previous price objective of $55.00. JPMorgan Chase & Co.’s target price points to a potential upside of 26.32% from the company’s current price.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.38% during mid-day trading on Monday, hitting $46.37. The stock had a trading volume of 387,000 shares. Agios Pharmaceuticals has a 52 week low of $15.77 and a 52 week high of $49.79. The stock has a 50-day moving average of $38.44 and a 200-day moving average of $33.54. The company’s market cap is $1.574 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, May 8th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.38) by $0.01. On average, analysts predict that Agios Pharmaceuticals will post $-1.47 earnings per share for the current fiscal year.
In other Agios Pharmaceuticals news, COO John Duncan Higgons sold 7,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $34.47, for a total value of $241,290.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Several other analysts have also recently commented on the stock. Analysts at Zacks upgraded shares of Agios Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $44.80 price target on the stock. Analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals from $51.00 to $65.00 in a research note on Monday, April 7th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $51.70.
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.